Fifteen years ago, after the death of his favorite uncle, Steven Rosen committed his grief to paper.
Irwin H. Krakoff, former director of the University of Vermont Cancer Center who has also served in key jobs at Memorial Sloan-Kettering Cancer Center and MD Anderson Cancer Center, died on Aug. 9 in Savannah, GA.
Boris C. Pasche was named president and CEO of the Barbara Ann Karmanos Cancer Institute and chair of the Wayne State University School of Medicine’s Department of Oncology.
Larry J. Copeland passes The GOG Foundation Inc. presidential gavel to Thomas J. Herzog.Thomas J. Herzog was elected the president of The GOG Foundation Inc at the NRG Oncology summer meeting on July 20.
Alexander Price was named assistant professor in the Gene Expression and Regulation Program of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
Yu “Sunny” Liu was named assistant professor in the nuclear dynamics and cancer research program and the Cancer Epigenetics Institute at Fox Chase Cancer Center.
Michael G. Tecce was named assistant professor in the Division of Plastic and Reconstructive Surgery in the Department of Surgical Oncology at Fox Chase Cancer Center.
Researchers at City of Hope were awarded $32.3 million from the California Institute for Regenerative Medicine to support three novel phase I clinical trials evaluating innovative cell and gene therapy treatments for patients with acute myeloid leukemia and other diseases.
Baylor, Texas Children’s awarded $7.6M to study disparities for Latino survivors of childhood cancer
Researchers at Baylor College of Medicine and Texas Children’s Cancer Center were awarded more than $7.6 million over four years from NCI to comprehensively study late effects of childhood cancer in a diverse population of childhood cancer survivors, including their medical, neurocognitive, and psychosocial outcomes. In addition, they will evaluate potential educational and sociodemographic barriers to obtaining survivorship care.
Gracell Biotechnologies Inc. has entered into a purchase agreement with a group of institutional and accredited healthcare specialist investors. Gracell will receive $100 million in proceeds from the private placement of ordinary shares, with up to an additional $50 million.
